Gain Therapeutics, Inc. (GANX)
| Market Cap | 83.18M +51.3% |
| Revenue (ttm) | n/a |
| Net Income | -21.24M |
| EPS | -0.58 |
| Shares Out | 42.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 868,683 |
| Open | 2.040 |
| Previous Close | 2.020 |
| Day's Range | 1.880 - 2.040 |
| 52-Week Range | 1.410 - 4.340 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 7.20 (+269.23%) |
| Earnings Date | May 11, 2026 |
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company’s drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for GANX stock is "Strong Buy." The 12-month stock price target is $7.2, which is an increase of 269.23% from the latest price.
News
Gain Therapeutics presents data from Phase 1b study of GT-02287
Gain Therapeutics (GANX) announced the presentation of an oral presentation at the 3rd International GBA1 Meeting 2026, held May 22-23, 2026, in Phoenix, AZ. The oral presentation outlined new clinica...
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph cont...
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Gain Therapeutics (GANX) to $8 from $10 but keeps a Buy rating on the shares. The company’s GT-02287 program…
Gain Therapeutics Earnings release: Q1 2026
Gain Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Gain Therapeutics Quarterly report: Q1 2026
Gain Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
“The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and…
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the n...
Gain Therapeutics Slides: Corporate presentation
Gain Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Gain Therapeutics Proxy statement: Proxy filing
Gain Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Gain Therapeutics Proxy statement: Proxy filing
Gain Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics management to meet with Maxim
Analyst Jason McCarthy holds a meeting with management, April 22-23 hosted by Maxim.
Gain Therapeutics Slides: Corporate presentation
Gain Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Gain Therapeutics Annual report: Q4 2025
Gain Therapeutics has published its Q4 2025 annual report on March 26, 2026.
Gain Therapeutics Earnings release: Q4 2025
Gain Therapeutics released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
Cash, cash equivalent and marketable securities were $20.8 million as of December 31, 2025, compared to $10.4M as of December 31, 2024. “We are encouraged by the progress made in…
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain Therapeutics Transcript: The 38th Annual Roth Conference
A novel approach to Parkinson's targets disease biology by stabilizing GCase, with early clinical data showing safety, biomarker engagement, and stable motor scores. Phase II trials will stratify patients by biomarkers and begin in Q3, with further pipeline candidates in development.
Gain Therapeutics to Present at the 38th Annual ROTH Conference
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the...
Gain announces presentations on Phase 1b clinical study of GT-02287
Gain Therapeutics (GANX) announced the presentation of an oral presentation and poster at AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders,...
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit...
Gain Therapeutics provides regulatory update on GT-02287
The Company submitted an IND to conduct a placebo-controlled, dose-range-finding Phase 2 clinical trial of GT-02287 in the United States. In March 2026, the Company submitted a response to the…
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of ...
Gain Therapeutics Slides: Corporate presentation
Gain Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 8, 2026.
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...